Navigation Links
Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
Date:6/2/2009

nt of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
2. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. Pharmasset Reports Fiscal Year End 2008 Financial Results
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
7. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... -- ResMed Inc. (NYSE: RMD ) today announced that ... June 30, 2015 results on Thursday, July 30, 2015, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/2/2015)... 2, 2015 Releases of the ... Aedes aegypti , , reduced the dengue mosquito ... by 95%, well below the modelled threshold ... , The journal PLOS Neglected Tropical Diseases ... genetically engineered mosquitoes. The results showed that in Juazeiro ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/nlfg34/cancer ) has ... Imaging and by Application - Forecast to 2020" report to ... to reach $13.1 Billion in 2020 from an estimated $7.1 Billion ... market is dominated by North America , followed ... and Rest of the World (RoW). The cancer diagnostics market in ...
Breaking Medicine Technology:ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3Global Cancer Diagnostics Market Report 2015 - Technology, Imaging and by Applications Forecasts to 2020 for the $13 Billion Industry 2
... 17, 2011 Attorneys representing a group of U.S. citizens ... the drug thalidomide have filed a lawsuit in federal court ... show the drug was widely distributed in the United States. ... to respond to a number of Freedom of Information Act ...
... WASHINGTON, Nov. 17, 2011 The proliferation of brand ... generics to more expensive brands, will increase costs by ... employers, unions, and state employee plans, according to new ... Care Management Association (PCMA).   The use of these ...
Cached Medicine Technology:Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide 2Hagens Berman: Patients Seek to Force FDA to Release Records Showing US Distribution of Thalidomide 3Brand Drug 'Copay Coupons' Undermine Generics, Raise Health Costs by $617 Million in Wisconsin 2
(Date:7/4/2015)... ... 2015 , ... When a hacker gains access to someone’s email account, it can lead to ... July 1st, the FTC issued a scam alert about a social engineering scam ... a password reset instigated by the hacker. All they have to do is click ...
(Date:7/3/2015)... , ... July 03, 2015 , ... ... Friend opened registration for a new SEO training system called "Page One ... for organic traffic generation has received glowing reviews from several well-known marketers. HonestyFirstReviews.com's ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... providers, has been retained to lead a national president recruitment for ... in the healthcare industry, B. E. Smith has recently placed more than 1,000 ...
(Date:7/3/2015)... ... 2015 , ... Talcum powder attorneys representing clients in national lawsuits announce the ... Center website. Just as the previous version did, the new website will serve as ... and ovarian cancer warning information. The site is routinely updated with news articles on ...
(Date:7/3/2015)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... and expose popular lies regarding proper relationships according to the bible. , ... the core of the subject by explaining why certain types of sexual relationships are ...
Breaking Medicine News(10 mins):Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... be only a dash and sprinkel away: Researchers with ... in addition to making food tastier, are an abundant ... when supplementing a balanced diet.Herbs have higher antioxidant activity ... researchers say. Their findings appear in the Journal of ...
... Sickle cell disease, sometimes called sickle cell anemia, is ... become sickle-shaped, which makes it difficult// for the cells ... the body's tissues. Young sickle cell patients who are ... from supplemental zinc, a mineral essential for growth and ...
... researchers at the Israel Deaconess Medical Center in Dallas, there ... impact that weight loss can make in decreasing the complications ... the first long-term study on how weight loss affects the ... cent of the population now classified as overweight, and diabetes ...
... sniff out men whose body odour is similar to that ... smells similar to a woman's father is likely to have ... humans produce are called pheromones. They are influenced to a ... system called the Major Histocompatibility Complex (MHC) . ,50 ...
... smoking accelerates the risk of heart disease, but now researchers ... development of a heart attack.This is because each cigarette appears ... the cardiovascular system.// ,In a study of heart attack ... within six hours of developing symptoms had bigger blood clots ...
... cell swallows a small capsule-shaped bacteria. The immune cells which ... way they should in space travellers and it could be ... Johnson Space Center (JSC) have been studying how immune cells ... health effects of space on astronauts.// ,It has been ...
Cached Medicine News:Health News:Herbs: rich soure of antioxidants 2Health News:Immune cells halt round in space 2
... more comfortable, and you will too., ... and to avoid the knotty problems associated ... ties, consider the Dale® Tracheostomy Tube Holder. ... narrow fastener tabs of the Dale® Tracheostomy ...
... securely in place. Soft strap features an ... Soft compliant foam laminate with elastic adjustment ... edema while still providing a snug fit. ... helps prevent sliding and patient irritation, and ...
... Percutaneous Dilation Tracheostomy Kits allow ... tracheostomy tube using the widely ... of a single-stage curved dilator. ... without the Portex® Blue Line ...
... Self-contained kits provide convenience and cost control. ... care trays offer a variety of wound ... management of the tracheostomized patient. , ... and trays with disposable inner cannula for ...
Medicine Products: